

PRESS RELEASE

Elekta's convertible debenture loan 98-01

Stockholm 12 June 2001

As announced earlier the last day for conversion of Elekta's convertible debentures is Friday 29 June 2001.

Up to now debentures totalling SEK 58,504,285 have been applied for conversion corresponding to 971,832 B-shares. Of these the Swedish Patent and Registration Office has on 8 June registered 550,764 new series B-shares corresponding to an increase in share capital of SEK 2,753,820. After this increase the total number of series B-shares amounts to 27,216,881 and the total number of shares including series A-shares amounts to 28,404,381. This includes applications to convert received until 29 May 2001.

Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective and cost efficient and gentle to the patient.

For further information, please contact:

Lars Jonsteg, VP Corporate Relations, Elekta AB (publ), tel. +46 8 587 254 82